May 10, 2024Recently, Beilu Pharmaceutical received a Drug Registration Certificate from the National Medical Products Administration for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets with a s...view
January 23, 2024Recently, Beilu Pharmaceutical's independently developed exclusive pure Chinese medicine formulation, Jiuwei Zhenxin granules, has been included in the "Double Heart Outpatient Construction S...view
April 21, 2021Recently, Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA).view
October 12, 2022"Building a multi-level R&D system and actively creating a second growth curve" is the development strategy of the company, and also one of the key tasks of the company in the next few y...view
February 24, 2023Recently, the "Wealth and Responsibility - Values of Enterprises" 2022 China Top 500 Charity List Conference was held in Chongqing. Since its inclusion in 2021, Beilu Pharmaceutical has been...view